Neurocrine Biosciences (NBIX) Net Cash Flow Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.13% |
| Mar 31, 2026 | -36.26% |
| Dec 31, 2025 | 28.95% |
| Sep 30, 2025 | 49.59% |
| Jun 30, 2025 | -21.11% |
| Mar 31, 2025 | -20.31% |
| Dec 31, 2024 | -15.52% |
| Sep 30, 2024 | 52.56% |
| Jun 30, 2024 | -41.95% |
| Mar 31, 2024 | 32.65% |
| Dec 31, 2023 | 4.50% |
| Sep 30, 2023 | 35.42% |
| Jun 30, 2023 | 55.71% |
| Mar 31, 2023 | -14.91% |
| Dec 31, 2022 | 42.78% |
| Sep 30, 2022 | 25.98% |
| Jun 30, 2022 | -19.50% |
| Mar 31, 2022 | -28.31% |
| Dec 31, 2021 | 30.68% |
| Sep 30, 2021 | -44.09% |